Statutory Instruments
2024 No. 1334
CONSUMER PROTECTION
The Cosmetic Products (Restriction of Chemical Substances) (No. 2) Regulations 2024
Made
11th December 2024
Laid before Parliament
17th December 2024
Coming into force
31st January 2025
The Secretary of State makes these Regulations in exercise of the powers conferred by Articles 31(1)(b), 31(1)(f) and 32(1)(b) of Regulation the Regulation ”)( 1 ).
In accordance with Article 31(1)(b) of the Regulation, the Secretary of State considers there is sufficient scientific evidence that there is a potential risk to human health arising from the use, in cosmetic products, of the substance set out in Schedule 2 to these Regulations.
In accordance with Article 31(1)(f) of the Regulation, the substances set out in Schedule 1 to these Regulations have been classified as CMR( 2 ) substances of category 1A, 1B or 2 under Regulation 3 ).
Citation, commencement and extent
1. —(1) These Regulations may be cited as the Cosmetic Products (Restriction of Chemical Substances) (No. 2) Regulations 2024 and come into force on 31st January 2025.
(2) These Regulations extend to England and Wales and Scotland.
Amendment to Regulation (EC) No 1223/2009
2. —(1) Regulation
(2) At the end of the table in Annex 2 (list of substances prohibited in cosmetic products), insert the entries set out in Schedule 1 to these Regulations.
(3) At the end of the table in Annex 3 (list of substances which cosmetic products must not contain except subject to the restrictions laid down), insert the entries set out in Schedule 2 to these Regulations.
Transitional Provisions
3. —(1) Notwithstanding the amendments in regulation 2(2), cosmetic products containing any of the substances set out in Schedule 1 to these Regulations at reference numbers 1680 to 1730 that are placed on the market on or before 20th April 2025 may continue to be made available on the market on or before 20th October 2025.
(2) Notwithstanding the amendments in regulation 2(2), cosmetic products containing any of the substances set out in Schedule 1 to these Regulations at reference numbers 1731 to 1743 that are placed on the market on or before 2nd September 2025 may continue to be made available on the market on or before 2nd March 2026.
(3) Notwithstanding the amendment in regulation 2(3), cosmetic products that are placed on the market on or before 20th June 2025 may continue to be made available on the market on or before 1st November 2025.
Justin Madders
Parliamentary Under-Secretary of State
Department for Business and Trade
11th December 2024
Schedules
Regulation 2(2)
Schedule 1 Amendments to Annex 2
| 1680 | Tetrafluoroethylene | 116-14-3 | 204-126-9 |
| 1681 | 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol; [DBMC] | 119-47-1 | 204-327-1 |
| 1682 | (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone | 688046-61-9 | 692-456-8 |
| 1683 | (RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate | 1101132-67-5 | |
| 1684 | 3-methylpyrazole | 1453-58-3 | 215-925-7 |
| 1685 | N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; Pydiflumetofen | 1228284-64-7 | |
| 1686 | N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}- 3-(difluoromethyl)-1-methyl-1Hpyrazole-4-carboxamide; Sedaxane | 874967-67-6 | |
| 1687 | Thiophanate-methyl (ISO); dimethyl (1,2- phenylenedicarbamothioyl)biscarbamat; dimethyl 4,4’-(o-phenylene)bis(3- thioallophanate) | 23564-05-8 | 245-740-7 |
| 1688 | Mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt | 8018-01-7 | |
| 1689 | Trinickel disulfide; nickel subsulfide; [1] heazlewoodite [2] | 12035-72-2 [1] 12035-71-1 [2] | 234-829-6 [1] – [2] |
| 1690 | 7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide | 106-87-6 | 203-437-7 |
| 1691 | 4-methylpentan-2-one; isobutyl methyl ketone (MIBK) | 108-10-1 | 203-550-1 |
| 1692 | Carbendazim (ISO); methyl benzimidazole-2-ylcarbamat | 10605-21-7 | 234-232-0 |
| 1693 | Dimethomorph (ISO); (E,Z)-4-(3-(4- chlorophenyl)-3-(3,4- dimethoxyphenyl)acryloyl)morpholine | 110488-70-5; (1135441-72-3) | 404-200-2 |
| 1694 | 1,2,4-triazole | 288-88-0 | 206-022-9 |
| 1695 | Flumioxazin (ISO); N-(7-fluoro-3,4- dihydro-3-oxo-4-prop-2-ynyl-2H-1,4- benzoxazin-6-yl)cyclohex-1-ene-1,2- dicarboximide | 103361-09-7 | |
| 1696 | Imazamox (ISO); (RS)-2-(4-isopropyl-4- methyl- 5-oxo-2-imidazolin-2-yl)-5- methoxymethylnicotinic acid | 114311-32-9 | |
| 1697 | Thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5- methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine | 153719-23-4 | 428-650-4 |
| 1698 | Triticonazole (ISO); (RS)-(E)-5-(4- chlorobenzylidene)-2,2-dimethyl-1-(1H1,2,4-triazol-1-ylmethyl)cyclopentanol | 138182-18-0 | |
| 1699 | Desmedipham (ISO); ethyl 3-phenylcarbamoyloxyphenylcarbamate | 13684-56-5 | 237-198-5 |
| 1700 | Tellurium dioxide | 7446-07-3 | 231-193-1 |
| 1701 | Tellurium | 13494-80-9 | 236-813-4 |
| 1702 | Fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5- (trifluoromethyl)-2- pyridylmethyl]benzamide | 239110-15-7 | 607-285-6 |
| 1703 | Daminozide (ISO); 4-(2,2- dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid | 1596-84-5 | 216-485-9 |
| 1704 | Benzophenone | 119-61-9 | 204-337-6 |
| 1705 | Acetamiprid (ISO); (1E)-N-[(6- chloropyridin-3- yl)methyl]-N'-cyano-N-methylethanimidamide; (E)-N 1 -[(6- chloro-3-pyridyl)methyl]-N 2 -cyano-N 1 – methylacetamidine | 135410-20-7 | 603-921-1 |
| 1706 | Theophylline; 1,3-dimethyl-3,7-dihydro-1 H -purine-2,6-dione | 58-55-9 | 200-385-7 |
| 1707 | N -(2-nitrophenyl)phosphoric triamide | 874819-71-3 | 477-690-9 |
| 1708 | Dibutyltin di(acetate) | 1067-33-0 | 213-928-8 |
| 1709 | Dibutyltin bis(2-ethylhexanoate) | 2781-10-4 | 220-481-2 |
| 1710 | Cumene | 98-82-8 | 202-704-5 |
| 1711 | Barium diboron tetraoxide | 13701-59-2 | 237-222-4 |
| 1712 | 2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3- propanediyldiacrylate; 2,2- bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate | 15625-89-5 | 239-701-3 |
| 1713 | Quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone | 2797-51-5 | 220-529-2 |
| 1714 | Pendimethalin (ISO); N-(1-ethylpropyl)- 2,6-dinitro-3,4-xylidene | 40487-42-1 | 254-938-2 |
| 1715 | Isoflucypram (ISO); N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide | 1255734-28-1 | |
| 1716 | Dimoxystrobin (ISO); (2E)-2-{2-[(2,5- dimethylphenoxy)methyl]phenyl}-2- (methoxyimino)-N-methylacetamide; (E)-2- (methoxyimino)-N-methyl-2-[a-(2,5-xylyloxy)-o-tolyl]acetamide | 149961-52-4 | 604-712-8 |
| 1717 | 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2- bis(bromomethyl)propan-1-ol | 36483-57-5; 1522-92-5 | 253-057-0 |
| 1718 | 2,4,6-tri-tert-butylphenol | 732-26-3 | 211-989-5 |
| 1719 | Ammonium bromide | 12124-97-9 | 235-183-8 |
| 1720 | Divanadium pentaoxide; Vanadium pentoxide | 1314-62-1 | 215-239-8 |
| 1721 | Bentazone (ISO); 3-isopropyl-2,1,3- benzothiadiazine-4-one-2,2-dioxide | 25057-89-0 | 246-585-8 |
| 1722 | Margosa extract. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] | 84696-25-3 | 283-644-7 |
| 1723 | Valifenalate (ISO); methyl N-(isopropoxycarbonyl)-L-valyl- (3RS)-3- (4-chlorophenyl)-β-alaninate | 283159-90-0 | |
| 1724 | Isopyrazam (ISO); reaction mass of 3-(difluoromethyl)-1-methyl-N- [(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4- methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4- tetrahydro-9-isopropyl-1,4-methanonaphthalen-5- yl]pyrazole-4-carboxamide [>78% syn isomers ≤ 15% anti isomers relative content]; | 881685-58-1 | |
| 1725 | Perfluoroheptanoic acid; tridecafluoroheptanoic acid | 375-85-9 | 206-798-9 |
| 1726 | 4,4’-sulphonyldiphenol; bisphenol S | 80-09-1 | 201-250-5 |
| 1727 | 6-[C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid (tetra-PSCA) | 2156592-54-8 | 701-118-1 |
| 1728 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid (Penta-PSCA) | 701-162-1 | |
| 1729 | [C12-18-alkyl-(branched, unsaturated)- 2,5-dioxopyrrolidin-1-yl] hexanoic acid, sodium and tris(2-hydroxyethyl) ammonium salts; (penta-PSCA Na-TEA) | 701-271-4 | |
| 1730 | 1,3,5-triazine-2,4,6-triamine; melamine | 108-78-1 | 203-615-4 |
| 1731 | Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate | 577705-90-9 | 479-100-5 |
| 1732 | Benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) | 75768-65-9 | 278-305-5 |
| 1733 | Reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) | ||
| 1734 | Reaction mass of 4,4'-[2,2,2-trifluoro 1-(trifluoromethyl)ethylidene] diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1- (trifluoromethyl)ethylidene]bis[phenol] (1:1) | ||
| 1735 | Reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2- ((2,3-epoxypropoxy)methyl) -2-hydroxymethyl butane | ||
| 1736 | 4,4'-[2,2,2-trifluoro-1- (trifluoromethyl)ethylidene]diphenol; bisphenol AF | 1478-61-1 | 216-036-7 |
| 1737 | Transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl trans-2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate | 118712-89-3 | 405-060-5 |
| 1738 | Salts of 2-ethylhexanoic acid | ||
| 1739 | Benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine | 1861-40-1 | 217-465-2 |
| 1740 | N,N-dimethyl-p-toluidine | 99-97-8 | 202-805-4 |
| 1741 | 4-nitrosomorpholine | 59-89-2 | |
| 1742 | 3,3'-dimethylbiphenyl 4,4'-diyl diisocyanate | 91-97-4 | 202-112-7 |
| 1743 | Foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea | 173159-57-4 |
Regulation 2(3)
Schedule 2 Amendment to Annex 3
| 323 | 5-hydroxy-2-(hydroxymethyl)pyran-4-one | Kojic acid | 501-30-4 | 207-922-4 | Face and hand products | 1% |
EUR 2009/1223 was incorporated into domestic law by virtue of section 3(1) of the European Union (Withdrawal) Act 2018 (c. 16) and was amended by S.I. 2019/696 ; there are other amending instruments but none is relevant.
For the definition of “CMR” see Article 2(1)(va) of the Regulation.
EUR 2008/1272 was incorporated into domestic law by virtue of section 3(1) of the European Union (Withdrawal) Act 2018; relevant amending instruments are S.I. 2019/720 and S.I. 2020/1567 .